Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Novartis allies with Conatus in $722mm liver disease R&D pact; later terminated

Executive Summary

Novartis AG and Conatus Pharmaceuticals Inc. will collaborate on the development and commercialization of Conatus' emricasan (IDN6556) alone for nonalcoholic steatohepatitis (NASH) and in combination with other farnesoid X receptor (FXR) agonists the Big Pharma has in its pipeline for NASH and other chronic liver diseases.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies